Evaluation of gradient strip diffusion for susceptibility testing of aztreonam-avibactam in metallo-β-lactamase-producing Enterobacterales

被引:0
|
作者
Lemon, Jamie K. [1 ,2 ]
Jankowsi-Romano, Cheryl [1 ]
Duong, Scott [1 ,2 ]
Juretschko, Stefan [1 ,2 ]
Streva, Vincent A. [1 ,2 ]
机构
[1] Northwell Hlth Clin Labs, New York, NY 10075 USA
[2] Donald & Barbara Zucker Sch Med Hofstra Northwell, Manhasset, NY 11549 USA
关键词
metallo-beta-lactamase; aztreonam-avibactam; antimicrobial susceptibility testing; NDM; gradient strip diffusion;
D O I
10.1128/jcm.00649-24
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The emergence of metallo-beta-lactamase (MBL)-producing Enterobacterales presents unique clinical treatment challenges. Recently developed beta-lactam/ beta-lactamase inhibitor combination agents, while effective against other carbapenemase-producing organisms, are notably ineffective against MBL producers. While MBLs do not hydrolyze monobactams (aztreonam), many MBL-producing organisms are resistant to aztreonam through alternate mechanisms, leaving cefiderocol as the sole monotherapy treatment option recommended for MBL producers. Recent guidelines for the treatment of MBL-harboring organisms have added combination therapy with aztreonam and ceftazidime-avibactam, using ceftazidime-avibactam as a source of the beta-lactamase inhibitor avibactam. Current laboratory testing options for the combination of aztreonam-avibactam are limited to broth microdilution (BMD) and broth disk elution (BDE) methods, which are not practical in most clinical laboratories. In this study, we evaluated the performance of aztreonam/avibactam gradient strips on 103 MBL-producing Enterobacterales patient isolates as well as an additional 31 isolates from the CDC AR Bank. All MBL Enterobacterales patient isolates included in this study harbored a New Delhi metallo-beta-lactamase (blaNDM) gene. Essential agreement of gradient strip minimal inhibitory concentrations (MICs) for patient isolates compared to BMD was 93.2%. While there are no established breakpoints for aztreonam-avibactam, category agreement (CA) for patient isolates was 97.1% when using the CLSI aztreonam breakpoints. There were no major or very major errors observed. There were three minor errors. Precision for aztreonam-avibactam gradient strip diffusion was 100%. These data demonstrate that the use of gradient strip diffusion for aztreonam-avibactam MIC determination in MBL-producing Enterobacterales is a viable option for clinical laboratories.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli
    Tao, Lili
    Dahlquist, Ashley
    Harris, Harley
    Jacobs, Emily
    Wenzler, Eric
    Simner, Patricia J.
    Humphries, Romney
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (10)
  • [32] Exploring Aztreonam in Combination with Ceftazidime-Avibactam or Meropenem-Vaborbactam as Potential Treatments for Metallo- and Serine-β-Lactamase-Producing Enterobacteriaceae
    Biagi, M.
    Wu, T.
    Lee, M.
    Patel, S.
    Butler, D.
    Wenzler, E.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (12)
  • [33] Successful treatment of Verona integron-encoded metallo-β-lactamase-producing Klebsiella pneumoniae infection using the combination of ceftazidime/avibactam and aztreonam
    Pelaez Bejarano, Ana
    Sanchez-del Moral, Raquel
    Montero-Perez, Olalla
    Javier Martinez-Marcos, Francisco
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2022, 29 (02) : 113 - 115
  • [34] The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases
    Mauri, Carola
    Maraolo, Alberto Enrico
    Di Bella, Stefano
    Luzzaro, Francesco
    Principe, Luigi
    ANTIBIOTICS-BASEL, 2021, 10 (08):
  • [35] In Vitro Activities of Aztreonam-avibactam and Comparator Agents against Metallo-,B-lactamase-producing Enterobacterales Collected in the Middle East and Africa, ATLAS Global Surveillance Program, 2018-2022
    Estabrook, Mark
    Stone, Gregory
    Sahm, Daniel
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2025, 152
  • [36] Human Simulated Studies of Aztreonam and Aztreonam-Avibactam To Evaluate Activity against Challenging Gram-Negative Organisms, Including Metallo-β-Lactamase Producers
    Crandon, Jared L.
    Nicolau, David P.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (07) : 3299 - 3306
  • [37] Evaluation of Metallo-β-Lactamase Susceptibility Testing in a Physiologic Medium
    Asempa, Tomefa E.
    Bajor, Hannah
    Mullins, Jessica H.
    Hartnett, Janice
    Nicolau, David P.
    MICROBIOLOGY SPECTRUM, 2021, 9 (03):
  • [38] Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales
    Kelley, C. J.
    Kennedy-Mendez, A.
    Walser, O. N.
    Thwaites, M. T.
    Arhin, F. F.
    Pillar, C. M.
    Hufnagel, D. A.
    MICROBIOLOGY SPECTRUM, 2022, 10 (06):
  • [39] In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations
    Yoshizumi, Ayumi
    Ishii, Yoshikazu
    Aoki, Kotaro
    Testa, Raymond
    Nichols, Wright W.
    Tateda, Kazuhiro
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2015, 21 (1-2) : 148 - 151
  • [40] BUDGET IMPACT ANALYSIS OF AZTREONAM-AVIBACTAM (ATM-AVI) FOR THE TREATMENT OF INFECTIONS CAUSED BY CONFIRMED AND SUSPECTED METALLO B-LACTAMASE (MBL)-PRODUCING ENTEROBACTERALES IN ITALY
    Falcone, M.
    Bao, X.
    Woodcock, F.
    Di Virgilio, R.
    Pereira, Vidal M. A.
    Kantecki, M.
    Gheorghe, M.
    VALUE IN HEALTH, 2024, 27 (12) : S99 - S99